pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›calendar
  3. ›earnings
earnings
save

NEUROCRINE BIOSCIENCES INC earnings

October 28, 2026$NBIXupdated 19d ago
community read0 votes

Anticipated earnings call for NEUROCRINE BIOSCIENCES INC ($NBIX).

view source ↗
Data sources
yahoo earnings
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

same company · ±60 days · 1

  • earningsNEUROCRINE BIOSCIENCES INC earningsNov 2, 2026

related news · 8

  • biospaceFDA uncages Aardvark’s Prader-Willi study after new data cleared safety concerns↗
  • statSTAT+: Verastem’s KRAS inhibitor shows promise in pancreatic cancer↗
  • statAfter a melanoma diagnosis, mRNA cancer vaccine delivered a patient hope — and a path forward↗
  • statCompass Pathways CEO: Psychedelics company will ‘go slow before we go fast’↗
  • statSTAT+: FDA adcomm members’ ties to industry under scrutiny↗
  • statSTAT+: Pharmalittle: We’re reading about concerns over a rare disease drug, pharma payments to docs, and more↗
  • statHow many ways can the Trump administration clamp down on international researchers?↗
  • statSTAT+: Concerns grow on safety issues tied to Neurocrine Biosciences rare disease drug↗

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?